Abstract
Lipid X, a monosaccharide precursor of lipid A, has been found to prevent death in animals given a lethal dose of endotoxin, but the mechanism of this protective effect is unknown. We previously reported that lipid X blocks endotoxin-induced priming of human neutrophils in a manner consistent with competitive inhibition. To determine the molecular requirements for this antiendotoxin activity, we studied several derivatives of lipid X using the neutrophil priming assay. Neutrophil priming was quantitated by measuring stimulated superoxide (O2 −) release. The removal of either acyl group from lipid X or even the simple change of the amide to an ester linkage at C2 of the glucosamide ring resulted in a marked loss of antagonism. Monosaccharide analogues, structurally related to native lipid A by the presence of acyloxyacyl side chains, demonstrated marked inhibition of endotoxin-induced priming at low concentrations but an endotoxin-like, priming effect at high concentrations. The addition of a phosphate group at position 4 of the sugar moiety was the only modification studied so far that produced a pure antagonist with increased antiendotoxin activity. Demonstration of these structural requirements for the antiendotoxin activity of lipid A analogues supports the hypothesis that this effect may be mediated via specific cellular binding sites. Lipid X derivatives may be useful for studying the interaction of endotoxin with cells and their antiendotoxin activity may prove beneficial in the treatment of septicemia.
Similar content being viewed by others
REFERENCES
D. C. Morrison and J. L. Ryan. Adv. Immun. 28:293–450 (1971).
S. M. Wolff and J. V. Bennett. N. Engl. J. Med. 291:733 (1974).
C. S. Bryan, K. L. Reynolds, and E. R. Brenner. Rev. Infect. Dis. 5:629–638 (1983).
B. L. Ray, G. Painter, and C. R. H. Raetz. J. Biol. Chem. 259:4852–4859 (1984).
R. A. Proctor, J. A. Will, K. E. Burhop, and C. R. H. Raetz. Infect. Immun. 52:905–907 (1986).
D. T. Golenbock, J. A. Will, C. R. H. Raetz, and R. A. Proctor. Infect. Immun. 55:2471–2476 (1987).
R. L. Danner, K. A. Joiner, and J. E. Parrillo. J. Clin. Invest. 80:605–612 (1987).
L. A. Guthrie, L. C. McPhail, P. M. Henson, and R. B. Johnston. J. Exp. Med. 160:165–167 (1984).
I. Macher. Carbohydr. Res. 21:79–84 (1987).
D. C. Morrison and J. A. Rudbach. Contemp. Top. Mol. Immunol. 8:187–218 (1981).
M. E. Doerfler, R. L. Danner, J. H. Shelhamer, and J. E. Parrillo. J. Clin. Invest. 83:970–977 (1989).
J. Grabarek, S. Timmons, and J. Hawiger. J. Clin. Invest. 82:964–971 (1988).
A. A. Aderem, K. A. Albert, M. M. Keum, J. K. T. Wang, P. Greengard, and Z. A. Cohn. Nature 332:362–364 (1988).
S. J. H. Van Deventer, H. R. Buller, J. W. TenCate, A. Sturk, and W. Pauw. Lancet 1:605–609 (1988).
B. Beutler, N. Krochin, I. W. Milsark, C. Luedke, and A. Cerami. Science 232:977–980 (1986).
A. C. Heflin and K. L. Brigham. J. Clin. Invest. 68:1253–1260 (1981).
M. M. Parker, J. H. Shelhamer, C. Natanson, D. W. Alling, and J. E. Parrillo. Crit. Care Med. 15:923–929 (1987).
G. S. Worthen, C. Haslett, A. J. Rees, R. S. Gumbay, J. E. Henson, and P. M. Hensen. Am. Rev. Respir. Dis. 136:19–28 (1987).
R. S. Munford and C. L. Hall. Science 234:203–205 (1986).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Danner, R.L., Van Dervort, A.L., Doerfler, M.E. et al. Antiendotoxin Activity of Lipid A Analogues: Requirements of the Chemical Structure. Pharm Res 7, 260–263 (1990). https://doi.org/10.1023/A:1015874012484
Issue Date:
DOI: https://doi.org/10.1023/A:1015874012484